Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-cash Items (2020 - 2025)

Historic Non-cash Items for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $106.8 million.

  • Janux Therapeutics' Non-cash Items rose 176762.72% to $106.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.8 million, marking a year-over-year increase of 176762.72%. This contributed to the annual value of $361.6 million for FY2024, which is 206096.93% up from last year.
  • Per Janux Therapeutics' latest filing, its Non-cash Items stood at $106.8 million for Q3 2025, which was up 176762.72% from $98.7 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Non-cash Items high stood at $361.6 million for Q4 2024, and its period low was $5.0 million during Q1 2022.
  • Over the past 5 years, Janux Therapeutics' median Non-cash Items value was $26.4 million (recorded in 2022), while the average stood at $82.8 million.
  • As far as peak fluctuations go, Janux Therapeutics' Non-cash Items crashed by 9292.29% in 2022, and later soared by 468686.64% in 2024.
  • Janux Therapeutics' Non-cash Items (Quarter) stood at $63.0 million in 2021, then plummeted by 52.65% to $29.8 million in 2022, then crashed by 43.86% to $16.7 million in 2023, then soared by 2060.97% to $361.6 million in 2024, then tumbled by 70.45% to $106.8 million in 2025.
  • Its Non-cash Items stands at $106.8 million for Q3 2025, versus $98.7 million for Q2 2025 and $131.2 million for Q1 2025.